These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8588236)

  • 41. Cyclosporin for atopic dermatitis in children.
    Harper JI; Berth-Jones J; Camp RD; Dillon MJ; Finlay AY; Holden CA; O'Sullivan D; Veys PA
    Dermatology; 2001; 203(1):3-6. PubMed ID: 11549791
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyclosporin A monitoring in Australia: consensus recommendations.
    Morris RG; Tett SE; Ray JE
    Ther Drug Monit; 1994 Dec; 16(6):570-6. PubMed ID: 7878696
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Distribution of cyclosporin in organ transplant recipients.
    Akhlaghi F; Trull AK
    Clin Pharmacokinet; 2002; 41(9):615-37. PubMed ID: 12126456
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral.
    Wang CH; Ko WJ; Chou NK; Wang SS
    Transplant Proc; 2004 Oct; 36(8):2386-7. PubMed ID: 15561257
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of low and high density lipoproteins on renal cyclosporine A and cyclosporine G disposition in the isolated perfused rat kidney.
    Strong ML; Ueda CT
    Pharm Res; 1997 Oct; 14(10):1466-71. PubMed ID: 9358563
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies--a method suitable for small (<1 mg) samples.
    Noll BD; Coller JK; Somogyi AA; Morris RG; Russ GR; Hesselink DA; van Gelder T; Sallustio BC
    Ther Drug Monit; 2011 Dec; 33(6):688-93. PubMed ID: 22105584
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunosuppressive drugs in paediatric liver transplantation.
    van Mourik ID; Kelly DA
    Paediatr Drugs; 2001; 3(1):43-60. PubMed ID: 11220404
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of EMIT and FPIA methods for the detection of cyclosporin A blood levels: does impaired liver function make a difference?
    Witzke O; Heemann U; Thesing A; Wolfhard U; Erhard J; Philipp T; Michel MC
    Eur J Clin Pharmacol; 1997; 52(5):413-6. PubMed ID: 9272414
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of whole-blood cyclosporin G by liquid chromatography in renal transplant recipients.
    McBride JH; Kim SS
    J Clin Lab Anal; 1995; 9(4):238-42. PubMed ID: 7562241
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of cyclosporine on the development of immunosuppressive therapy in liver transplantation.
    Casanovas Taltavull T
    Transplant Proc; 2004 Mar; 36(2 Suppl):291S-294S. PubMed ID: 15041355
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients.
    Gregoor PJ; de Sévaux RG; Hené RJ; Hesse CJ; Hilbrands LB; Vos P; van Gelder T; Hoitsma AJ; Weimar W
    Transplantation; 1999 Nov; 68(10):1603-6. PubMed ID: 10589962
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of three methods for cyclosporine therapeutic monitoring.
    Jebabli N; Klouz A; Bahlous A; Gaïes E; Trabelsi S; Lakhal M; Belkahia C
    Transplant Proc; 2007 Oct; 39(8):2557-9. PubMed ID: 17954172
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them.
    Shaw LM; Kaplan B; Kaufman D
    Clin Chem; 1996 Aug; 42(8 Pt 2):1316-21. PubMed ID: 8697605
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels.
    Heydendael VM; Spuls PI; Ten Berge IJ; Opmeer BC; Bos JD; de Rie MA
    Br J Dermatol; 2002 Jul; 147(1):122-9. PubMed ID: 12100194
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rationale for monitoring cyclosporine concentration at 2 hours after administration in infants posttransplantation.
    Furlan V; Lykavieris P; Maubert MA; Habes D; Debray D
    Transplant Proc; 2009 Oct; 41(8):3333-4. PubMed ID: 19857744
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Therapeutic monitoring of cyclosporine A].
    Komzáková I; Safarcík K; Brozmanová H; Grundmann M
    Ceska Slov Farm; 2002 Jul; 51(4):159-67. PubMed ID: 12183901
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Experience with cyclosporine in the Canary Islands.
    Hernández D
    Transplant Proc; 2004 Mar; 36(2 Suppl):120S-124S. PubMed ID: 15041320
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral study group.
    Marsh CL
    Ther Drug Monit; 1999 Feb; 21(1):27-34. PubMed ID: 10051051
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs.
    Steffan J; Strehlau G; Maurer M; Rohlfs A
    J Vet Pharmacol Ther; 2004 Aug; 27(4):231-8. PubMed ID: 15305852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.